Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma
- DOI
- 10.1186/s40164-025-00610-1
- Published
- 2025-03-05
- Container
- Experimental Hematology & Oncology
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1186/s40164-025-00610-1,
title = {Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma},
author = {Loretta J. Nastoupil and Ashley Bonner and Pearl Wang and Lamees Almuallem and Jigar Desai and Thalia Farazi and Jinender Kumar and Saurabh Dahiya},
year = {2025},
journal = {Experimental Hematology \& Oncology},
doi = {10.1186/s40164-025-00610-1},
url = {https://doi.org/10.1186/s40164-025-00610-1}
}RIS
TY - JOUR TI - Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma AU - Loretta J. Nastoupil AU - Ashley Bonner AU - Pearl Wang AU - Lamees Almuallem AU - Jigar Desai AU - Thalia Farazi AU - Jinender Kumar AU - Saurabh Dahiya PY - 2025 JO - Experimental Hematology & Oncology DO - 10.1186/s40164-025-00610-1 UR - https://doi.org/10.1186/s40164-025-00610-1 ER -
APA
Nastoupil, L. J., Bonner, A., Wang, P., Almuallem, L., Desai, J., Farazi, T., Kumar, J., & Dahiya, S. (2025). Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma. Experimental Hematology & Oncology. https://doi.org/10.1186/s40164-025-00610-1
Source records
- crossref · retrieved 2026-09-25T16:37:13.241Z